These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31932015)

  • 1. Short-term mortality in end-stage heart failure patients.
    Verdú-Rotellar JM; Calero E; Abellana R; Verdú-Soriano J; Vinyoles E; Del Val-García JL; Domingo M; Muñoz MA
    Aten Primaria; 2020; 52(7):477-487. PubMed ID: 31932015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
    Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between anemia and outcome in patients hospitalized for acute heart failure syndromes: findings from Beijing Acute Heart Failure Registry (Beijing AHF Registry).
    Ye SD; Wang SJ; Wang GG; Li L; Huang ZW; Qin J; Li CS; Yu XZ; Shen H; Yang LP; Fu Y; Zheng YA; Zhao B; Yu DM; Qin FJ; Zhou DG; Li Y; Liu FJ
    Intern Emerg Med; 2021 Jan; 16(1):183-192. PubMed ID: 32356137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precipitating factors of heart failure decompensation, short-term morbidity and mortality in patients attended in primary care.
    Verdu-Rotellar JM; Vaillant-Roussel H; Abellana R; Jevsek LG; Assenova R; Lazic DK; Torsza P; Glynn LG; Lingner H; Demurtas J; Borgström B; Gibot-Boeuf S; Muñoz MA
    Scand J Prim Health Care; 2020 Dec; 38(4):473-480. PubMed ID: 33201746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four-variable risk model in men and women with heart failure.
    Chyu J; Fonarow GC; Tseng CH; Horwich TB
    Circ Heart Fail; 2014 Jan; 7(1):88-95. PubMed ID: 24281135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe.
    Fröhlich H; Rosenfeld N; Täger T; Goode K; Kazmi S; Hole T; Katus HA; Atar D; Cleland JGF; Agewall S; Clark AL; Frankenstein L; Grundtvig M
    Heart; 2019 Aug; 105(16):1252-1259. PubMed ID: 30792238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-Term Mortality in Patients with Heart Failure at the End-of-Life Stages: Hades Study.
    Muñoz MA; Calero E; Duran J; Navas E; Alonso S; Argemí N; Casademunt M; Furió P; Casajuana E; Torralba N; Farre N; Abellana R; Verdú-Rotellar JM; On Behalf Of Hades Study
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
    Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
    Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of gender on outcomes in chronic systolic heart failure.
    Ng AC; Wong HS; Yong AS; Sindone AP
    Int J Cardiol; 2007 Apr; 117(2):214-21. PubMed ID: 17064798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
    Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
    Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M
    JAMA; 2012 Nov; 308(20):2108-17. PubMed ID: 23188027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction.
    Böhm M; Tschöpe C; Wirtz JH; Lokies J; Turgonyi E; Bramlage P; Lins K; Strunz AM; Tebbe U
    Clin Cardiol; 2015 Apr; 38(4):200-7. PubMed ID: 25733185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis.
    Mantziari L; Guha K; Khalique Z; McDonagh T; Sharma R
    Am J Cardiol; 2012 Jun; 109(11):1619-25. PubMed ID: 22465318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial.
    Oyanguren J; Garcia-Garrido L; Nebot-Margalef M; Latorre-García P; Torcal-Laguna J; Comín-Colet J; Roure J; González-Costello J; Manito N; García-Pinilla JM; Sánchez-Paule Y; Varela-Román A; Moure M; Segovia-Cubero J; Soria T; Arana-Arri E; Lekuona I;
    Rev Esp Cardiol (Engl Ed); 2021 Jun; 74(6):533-543. PubMed ID: 32591295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.